Celgene Takes a $411M Hit From Discontinuation of Crohn's Disease Trials
Celgene announced back in October that it was discontinuing its GED-0301 program for Crohn’s disease and now that decision is costing the company $411M.
Source: BioSpace
Celgene announced back in October that it was discontinuing its GED-0301 program for Crohn’s disease and now that decision is costing the company $411M.
Source: BioSpace